Levonorgestrel - Menopausal disorders
You are here : Home > Formulary Search > Levonorgestrel - Menopausal disorders
Status 1
- Intrauterine device (progestogen only)
- Mirena - licensed for endometrial protection but only for a duration of 4 years. Agreed to use for a duration of 5 years before replacement (off-label).
Documentation
PAD Profile
Levonorgestrel recommended for replacement every 5 years (off-label use) as per BMS: https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progestogens-and-endometrial-protection-APR2023-A.pdf
Other Indications
Below are listed other indications that Levonorgestrel is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Menopausal disorders.
- Clonidine hydrochloride
- Conjugated oestrogens
- Conjugated oestrogens with medroxyprogesterone
- Drospirenone
- Estradiol
- Estradiol with dydrogesterone
- Estradiol with levonorgestrel
- Estradiol with medroxyprogesterone
- Estradiol with norethisterone
- Estradiol with progesterone
- Ethinylestradiol
- Gabapentin
- Medroxyprogesterone acetate
- Paroxetine
- Pregabalin
- Progesterone
- St Johns Wort
- Tibolone
- Venlafaxine
Committee Recommendations (1)
The Surrey & North West Sussex Area Prescribing Committee updated their recommendations in line with NICE guidance NG23 Menopause diagnosis and management in May 2020.
Mirena is recommended for menopausal symptoms and a GREEN traffic light status has been agreed. Please refer to the Menopause -NG23 briefing paper attached below for further information (Page 11/12). The Mirena® IUS (52 mg LNG) is the only intrauterine system licensed as part of HRT and needs to be
changed every 5 years (licensed for 4 years; recommended by the Faculty of Sexual and Reproductive Healthcare (FRSH) and licensed in other EU countries for 5 years)